Manchester, UK, 14 January 2025
Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the Japan Patent Office (“JPO”) has granted Japanese patent 7570345, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS).
The patent, which is expected to provide exclusivity until at least 2040, protects the use of a cognitive digital biomarker as a way to identify patients most likely to respond to Monument’s MT1988 compound for CIAS, and other pro-cognitive drug targets. “Securing robust patent protection in Japan, a key global market, is a significant milestone for Monument Therapeutics,” said Jenny Barnett, Chief Executive Officer of Monument Therapeutics. “Efforts to develop effective pharmacological treatments for cognitive impairment associated with schizophrenia face challenges due to the biological diversity among patients. Our digital biomarker approach allows us to identify those most likely to benefit from MT1988, paving the way for more personalized and effective care for individuals facing this debilitating condition.”
MT1988, a novel formulation utilising well-characterised actives, is being investigated as a potential treatment for CIAS, and other psychiatric disorders. Combined with Monument’s patient stratification approach using a digital biomarker, MT1988 has the potential to offer improved safety and efficacy for patients with unmet medical needs.
